Researchers seek genetic route to autism test

Acacia Research Corporation of California, US, has announced that its subsidiary, CombiMatrix Molecular Diagnostics (CMDX) has entered into a partnership with The Centre for Applied Genomics (TCAG) in Toronto, Canada, with a view to translating new genomic discoveries into clinically relevant diagnostic tests.

The CombiMatrix Group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins.

An international consortium, which included TCAG scientists, recently completed the most comprehensive study of the genetic causes of autism. CMDX has access to, and plans to use, the published markers in upcoming versions of its Constitutional Genetic Array Test. The test will then screen for the more than 50 disorders currently handled by the array, as well as for these newly discovered genetic indicators of autism susceptibility.

CMDX's first CGAT test was launched last year and has demonstrated significant diagnostic utility. A second version of the CGAT developed with TCAG, is expected later this year, with the third version to be released by the end of the year. This third version is expected to incorporate all newly discovered genetic indicators of autism.

Autism is a spectrum disorder with a variable range of phenotypic presentation. It is believed that an accurate identification of the potential genetic causes could provide better management options for the patient.

Dr Steve Scherer, Director of TCAG, said of the partnership with CMDX: "It is exciting to have a partner like this to translate our genomic discoveries into clinically relevant and responsible diagnostic tests."